Not available.

Infections are a significant cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), with respiratory tract infections being predominant. This study evaluated the incidence of chronic lung diseases (asthma, COPD, and bronchiectasis) among 4,532 patients with CLL and their association with infection complications and outcomes. We found that bronchiectasis (5%), asthma (12.2%), and COPD

Not available.

Not available.

Not available.

Not available.

CAR T expansion has been linked to anti-tumor response in relapsed/refractory large B-cell lymphoma both in clinical trials and smaller real-world studies. Here, we present the largest multicenter real-world analysis to date, evaluating 262 patients treated with tisagenlecleucel or axicabtagene ciloleucel in second or subsequent relapse. Our findings underscore the complementary roles of multiparameter

Not available.

Multiple myeloma (MM) shows inherent clinical and biological heterogeneity, leading to variable treatment responses and outcomes. The complex molecular landscape of MM makes precise risk stratification through clinical genetic testing difficult. Thus, identifying better biomarkers is essential to enhance existing stratification methods and guide personalized therapy decisions. Here, we systematically

Not available.

Hematopoietic stem cell transplantation is a well-established treatment option for acquired aplastic anemia. Historically, upfront hematopoietic stem cell transplantation (HCT) with HLA-matched sibling donors is used in young patients and immunosuppressive therapy (IST) is used for all others. Over time, innovations in the transplant platform have decreased unwanted complications such as graft versus

Not available.

Cardiac response (CarR) is associated with survival in AL amyloidosis, but substantial variation exists in response kinetics. We investigated variables associated with deep CarRs to characterize the factors that govern organ recovery. Retrospective study of newly-diagnosed AL amyloidosis patients (n=401) diagnosed between 2010-2022 and assessable for CarR. CarRs were recorded at 6, 12, 24-months and

Proliferating multiple myeloma (MM) cells in the bone marrow fluctuate across various metabolic states to resist cancer treatments. Herein, we investigate how mitochondrial dynamics, which controls mitochondrial fitness via coordinated fission and fusion events, shapes MM cell metabolism impacting growth, survival and drug sensitivity. We identify MFF (Mitochondrial Fission Factor), a pivotal driver

Not available.

Not available.

The optimal management of isolated distal deep vein thrombosis (IDDVT) is uncertain. To assess the efficacy and safety of anticoagulation in patients with IDDVT we performed a systematic review and meta-analysis of randomized and cohort studies on anticoagulation for IDDVT. Efficacy outcomes included recurrent deep vein thrombosis (DVT), pulmonary embolism (PE), proximal progression of IDDVT, post-thrombotic

Not available.

Immune dysregulation and immunosuppression occur due to the pathophysiology and management of primary immune thrombocytopenia (ITP), which together may increase the risk of subsequent cancer. We investigated the cancer risk in ITP compared with the general population in a binational cohort study in Denmark and France. We identified 12,456 patients with ITP and 218,971 age-sex matched general population

The interaction between VWF and platelet αIIbβ3 is thought to be essential for clot formation at injury sites, but its biological properties remain poorly understood due to the complexity and overlap with other αIIbβ3 ligands. Here, we developed a novel binding assay using a recombinant αIIbβ3 headpiece to evaluate VWF-αIIbβ3 binding in plasma from 441 Zimmerman Program participants. The VWF:αIIbβ3

Accumulating evidence have highlighted the critical role of tumor-associated macrophages (TAMs) in promoting immune evasion and disease progression in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Combined single-cell RNA sequencing, flow cytometry, and immunohistochemistry studies of the innate immune compartment in bone marrow of MDS/AML reveal a shift toward a tumor-supportive

Multiple myeloma (MM) is characterized by genetic abnormalities in plasma cells, requiring precise genomic characterization for effective risk stratification and treatment. This study presents the Unique Molecular Assay (UMA) panel, a targeted DNA-sequencing approach designed to capture critical genomic aberrations in MM, including canonical immunoglobulin heavy chain translocations (t-IgH), copy number

Tafasitamab combined with lenalidomide was approved in Europe in 2021 for transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. Approval was based on the L-MIND study, which demonstrated a 57.5% overall response rate (ORR), 41.3% complete response (CR) rate, 12.1 months median progression-free survival (PFS), and 33.5 months median overall survival (OS) at five years

BCR::ABL1-positive chronic myelogenous leukemia (CML) presents with a typical phenotype in over 95 percent of cases. These are associated with a p210kDa oncoprotein (M-bcr genotype). In these cases, the consideration of CML is high on the differential diagnosis list and appropriate genetic studies to confirm the BCR::ABL1 oncogene are de rigueur. The elevated white cell count, dominant granulocytes

Not available.

Pulmonary hypertension (PH) is a frequent complication of Philadelphia-negative myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). However, its prognostic significance is understudied, thus we aimed to evaluate the effect of PH identified by echocardiography on risk of progression to secondary MF or acute leukemia in MPN patients

Not available.

Accurate detection of patients at high risk of treatment failure following first line immunochemotherapy in diffuse large B-cell lymphoma (DLBCL) is of paramount importance as patients might benefit from early treatment escalation. Recently, we introduced the International Metabolic Prognostic Index (IMPI) based on metabolic tumor volume (MTV), age and stage that outperformed the International Prognostic

Karyotyping, SNP arrays, fluorescence in situ hybridisation and next generation sequencing techniques have greatly improved our understanding of the genetic drivers of acute lymphoblastic leukemia (ALL). In the past years, another layer of genetic data has been added by the study of mutational signatures, patterns of somatic mutations that represent specific mutational mechanisms. Mutational signatures

Not available.

Not available.

Not available.

Not available.

Not available.

The therapeutic landscape in ALL has changed dramatically over the last decade. Allogeneic blood or marrow transplantation (AlloBMT) has also evolved and remains an important option for consolidation. We assessed the interplay between these factors by analyzing the outcomes of 251 adult ALL (214 B and 37 T ALL) patients undergoing alloBMT with post-transplantation cyclophosphamide (PTCy) across two

Core binding factor acute myeloid leukemia (CBF-AML) includes RUNX1::RUNX1T1 and CBFB::MYH11 AML. To investigate whether they should be regarded as distinct entities and treated separately, we retrospectively analyzed 536 patients with CBF-AML aged 60 years or younger. For CBFB::MYH11 AML, no outcome differences were observed between standard-dose (SD) and intermediate-dose (ID) cytarabine induction

Not available.

Not available.

Not available.

Donor lymphocyte infusion (DLI) is employed to either treat or prevent relapse in patients with hematologic malignancies, as well as to accelerate recovery of adaptive immunity, after allogeneic hematopoietic stem cell transplantation (allo-HSCT). With the increased use of DLI, there is renewed interest in the development of approaches able to prevent graft-versus-host disease (GvHD) reaction. In this

In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognostic value on overall survival and incidence of relapse of these methods across ELN2017 risk groups, using data from the HOVON-SAKK132 trial. In addition, we have evaluated

Not available.

Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other day (QOD; N = 216) and a reduced dose of 30 mg QOD (N = 66) in subjects failing other tyrosine kinase-inhibitors

The safety, quality and supply of donor-derived platelet units intended for transfusion have improved over the past decades but significant problems still remain. In vitroderived platelets offer a possible alternative but up-scaling production is hindered by our limited understanding of thrombopoiesis (the release of platelets by their mother cell, the megakaryocyte [MK]). Here, we have developed an

Prophylactic and pre-emptive donor lymphocyte infusion (pro/preDLI) is used to prevent haematological relapse of AML and MDS after allogeneic stem cell transplantation. For lack of prospective trials, outcome reports, risk factor analyses and published recommendations for DLI administration had to rely on registry studies, frequently limited by inconsistent reporting and missing data. Therefore, we

Older patients with classical Hodgkin lymphoma (cHL) have lower tolerance and inferior outcomes after standard chemotherapy regimens. To identify patient-derived indicators of frailty associated with outcome, we retrospectively analyzed patient and disease characteristics, treatment and outcome in a Norwegian population-based cohort of older (≥60 years) patients with cHL diagnosed 2000-2015. We included

Not available.

Current intensive chemotherapy regimens have improved overall survival in pediatric acute lymphoblastic leukemia (ALL) but fail to cure some high-risk patient subgroups. We observed that lysine methyltransferase 2A (KMT2A)-rearranged leukemia, an aggressive subset with a dismal prognosis, is particularly vulnerable to perturbations of the methionine cycle. We demonstrate that this methionine dependency

Not available.

Not available.

Not available.

Not available.

Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder with a short survival duration despite the use of novel therapeutics. PCL remains an understudied disease for which there is no current standard of care treatment. Knowledge on optimal novel drug sequencing, including the role and timing of hematopoietic stem cell transplant as primary and salvage therapy is needed. We conducted

Myelofibrosis (MF) is a progressive disease characterized by accumulation of extracellular matrix (ECM) in the bone marrow (BM) which impairs normal hematopoiesis. While Janus kinase (JAK) inhibitors reduce spleen volume and provide symptomatic improvement, they do not resolve BM fibrosis and may cause or exacerbate anemia and thrombocytopenia. An anti-fibrotic therapy capable of normalising BM microenvironment

Not available.

Not available.

Novel agents inducing deeper responses have improved the prognosis of patients with multiple myeloma (MM). To assess minimal residual disease (MRD) and stratify patients achieving complete response (CR), advanced technologies such as EuroFlow next-generation flow cytometry (NGF) and next-generation sequencing (NGS) are increasingly utilized. This prospective study evaluated responses in newly diagnosed

Anti-CD47 antibodies targeting macrophage immune checkpoints demonstrate benefit in clinical trial, particularly in combination with targeted therapies. This strategy faces challenges from suboptimal efficacy and on-target toxicity due to immunosuppressive tumor microenvironment (TME) and ubiquitous CD47 expression. Here, we report a novel oncolytic vaccine virus (OVV) that expressed therapeutic transgenes

CD47 overexpression has been associated with tumor cell survival. We present the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of evorpacept, a novel fusion protein comprising a high-affinity CD47-SIRPα immune checkpoint inhibitor to promote tumor-cell phagocytosis and inactive Fc domain to spare healthy cells, plus rituximab in patients with relapsed/refractory B-cell